|

Characterization of CD180 Protein Expression in Myeloid Hematological Malignancies by Flow Cytometry

RECRUITINGSponsored by University Hospital, Strasbourg, France
Actively Recruiting
SponsorUniversity Hospital, Strasbourg, France
Started2026-01-21
Est. completion2027-04-21
Eligibility
Age1 Year+
Healthy vol.Accepted

Summary

CD180 is a cell-surface protein recently identified through proteomic analysis as a potential target of interest in myeloid hematological malignancies. It may have diagnostic and monitoring potential, particularly in acute myeloid leukemia (AML). This monocentric, non-interventional, retrospective observational study aims to characterize CD180 expression by flow cytometry in pathological hematopoietic cells, particularly in AML, and in normal hematopoietic stem and progenitor cells (CD34+ cells). The study will use residual blood and bone marrow samples collected during routine care and otherwise intended for disposal by incineration, together with relevant clinical and laboratory data.

Eligibility

Age: 1 Year+Healthy volunteers accepted
Inclusion Criteria:

* Adult patients aged 18 years or older.
* Pediatric patients aged 1 to 17 years.
* Patients with confirmed or suspected acute myeloid leukemia who have undergone bone marrow aspiration as part of the diagnostic or relapse assessment.
* Patients whose stem cells are being assessed using a blood or bone marrow sample.
* Patients and/or their legal representatives, where applicable, informed by letter of the use of residual sample material for research purposes.
* No written objection documented in the medical record to the reuse of personal data for scientific research.

Exclusion Criteria:

* Patients and/or their legal representatives, where applicable, who have objected to the reuse of personal data for scientific research.
* Samples more than 72 hours old.
* Clotted samples.
* Samples with insufficient volume (less than 10 microliters).

Conditions4

Acute Myeloid LeukemiaCancerMyeloid Hematological MalignanciesNormal Hematopoietic Stem and Progenitor Cells

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.